News articles about SUMMIT THERAPEU/S (NASDAQ:SMMT) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. SUMMIT THERAPEU/S earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.389168821729 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Completely driverless cars might NEVER become a reality because they ‘might be forced to choose whether to cause death’ (thesun.co.uk)
- BMW questions feasibility of driverless cars (freemalaysiatoday.com)
- BMW Thinks Fully Autonomous Cars May Never Happen (bmwblog.com)
- Fully Autonomous Cars May Never Actually Be Allowed (carthrottle.com)
Shares of SUMMIT THERAPEU/S traded down $0.02, reaching $2.33, during midday trading on Friday, according to MarketBeat.com. 51,620 shares of the stock were exchanged, compared to its average volume of 113,884. The stock has a market capitalization of $32.53 million, a price-to-earnings ratio of -3.11 and a beta of 0.81. SUMMIT THERAPEU/S has a twelve month low of $2.16 and a twelve month high of $16.86.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last issued its quarterly earnings data on Tuesday, June 5th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.48 million. SUMMIT THERAPEU/S had a negative net margin of 33.36% and a negative return on equity of 105.24%. equities analysts forecast that SUMMIT THERAPEU/S will post -1.67 EPS for the current year.
Several equities analysts recently weighed in on SMMT shares. HC Wainwright set a $20.00 price target on shares of SUMMIT THERAPEU/S and gave the stock a “buy” rating in a report on Wednesday, April 18th. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price objective on shares of SUMMIT THERAPEU/S in a research note on Tuesday, June 12th. Janney Montgomery Scott started coverage on shares of SUMMIT THERAPEU/S in a research note on Wednesday, May 2nd. They set a “buy” rating and a $27.00 price objective on the stock. ValuEngine raised shares of SUMMIT THERAPEU/S from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research raised shares of SUMMIT THERAPEU/S from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 19th. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $14.63.
About SUMMIT THERAPEU/S
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Featured Article: NASDAQ Stock Market Explained
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.